TY - JOUR
T1 - Caveolin-1
T2 - A critical regulator of lung fibrosis in idiopathic pulmonary fibrosis
AU - Xiao, Mei Wang
AU - Zhang, Yingze
AU - Hong, Pyo Kim
AU - Zhou, Zhihong
AU - Feghali-Bostwick, Carol A.
AU - Liu, Fang
AU - Ifedigbo, Emeka
AU - Xu, Xiaohui
AU - Oury, Tim D.
AU - Kaminski, Naftali
AU - Choi, Augustine M.K.
PY - 2006/12/25
Y1 - 2006/12/25
N2 - Idiopathic pulmonary fibrosis (IPF) is a progressive chronic disorder characterized by activation of fibroblasts and overproduction of extracellular matrix (ECM). Caveolin-1 (cav-1), a principal component of caveolae, has been implicated in the regulation of numerous signaling pathways and biological processes. We observed marked reduction of cav-1 expression in lung tissues and in primary pulmonary fibroblasts from IPF patients compared with controls. We also demonstrated that cav-1 markedly ameliorated bleomycin (BLM)-induced pulmonary fibrosis, as indicated by histological analysis, hydroxyproline content, and immunoblot analysis. Additionally, transforming growth factor β1 (TGF-β1), the well-known profibrotic cytokine, decreased cav-1 expression in human pulmonary fibroblasts. cav-1 was able to suppress TGF-β1-induced ECM production in cultured fibroblasts through the regulation of the c-Jun N-terminal kinase (JNK) pathway. Interestingly, highly activated JNK was detected in IPF- and BLM-instilled lung tissue samples, which was dramatically suppressed by ad-cav-1 infection. Moreover, JNK1-null fibroblasts showed reduced smad signaling cascades, mimicking the effects of cav-1. This study indicates a pivotal role for cav-1 in ECM regulation and suggests a novel therapeutic target for patients with pulmonary fibrosis. JEM
AB - Idiopathic pulmonary fibrosis (IPF) is a progressive chronic disorder characterized by activation of fibroblasts and overproduction of extracellular matrix (ECM). Caveolin-1 (cav-1), a principal component of caveolae, has been implicated in the regulation of numerous signaling pathways and biological processes. We observed marked reduction of cav-1 expression in lung tissues and in primary pulmonary fibroblasts from IPF patients compared with controls. We also demonstrated that cav-1 markedly ameliorated bleomycin (BLM)-induced pulmonary fibrosis, as indicated by histological analysis, hydroxyproline content, and immunoblot analysis. Additionally, transforming growth factor β1 (TGF-β1), the well-known profibrotic cytokine, decreased cav-1 expression in human pulmonary fibroblasts. cav-1 was able to suppress TGF-β1-induced ECM production in cultured fibroblasts through the regulation of the c-Jun N-terminal kinase (JNK) pathway. Interestingly, highly activated JNK was detected in IPF- and BLM-instilled lung tissue samples, which was dramatically suppressed by ad-cav-1 infection. Moreover, JNK1-null fibroblasts showed reduced smad signaling cascades, mimicking the effects of cav-1. This study indicates a pivotal role for cav-1 in ECM regulation and suggests a novel therapeutic target for patients with pulmonary fibrosis. JEM
UR - http://www.scopus.com/inward/record.url?scp=33845899411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845899411&partnerID=8YFLogxK
U2 - 10.1084/jem.20061536
DO - 10.1084/jem.20061536
M3 - Article
C2 - 17178917
AN - SCOPUS:33845899411
SN - 0022-1007
VL - 203
SP - 2895
EP - 2906
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 13
ER -